Maximize profitability in the gastroenterology market: capitalize on your pricing and reimbursement opportunities
In the competitive gastroenterology market, your branded products for irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) face price pressure from:
- generic and biosimilars
- over-the-counter therapies
- new treatments with a plethora of mechanisms of action.
As a manufacturer of innovative therapies for gastroenterology, you need to optimize market access and profitability by considering the:
- optimal patient subpopulations for your products
- global product indication sequence.
Developing a global pricing and market access strategy for new gastroenterology medicines
We work with clients on projects in a range of gastroenterology indications, including:
- Crohn’s disease
- IBS
- ulcerative colitis.
Our clients benefit from unique, targeted insights on pricing challenges, health technology assessments, and policy stance from our global network of over 2,000 multidisciplinary clinicians and advisors.
We welcome the opportunity to connect you with our panel of experts to help solve your market access challenges.
Request a call
